TITLE

A Model to Transfer Trial-Based Pharmacoeconomic Analyses to Clinical Practice

AUTHOR(S)
Gandjour, Afschin
PUB. DATE
February 2011
SOURCE
PharmacoEconomics;2011, Vol. 29 Issue 2, p97
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
This article deals with the question of how to handle costs to enhance medication adherence in trial-based pharmacoeconomic analyses. It argues that resources to improve patient adherence have a clearly distinguishable impact on costs and utility and thus are relatively easy to exclude when transferring trial-based pharmacoeconomic analyses to clinical practice. It proposes a model that adjusts trial-based incremental costs and effectiveness for lower medication adherence in clinical practice. It shows that, contrary to conventional wisdom, drug cost effectiveness in clinical practice can be better than in clinical trials. This may have implications for policy recommendations, depending on how close trial-based cost effectiveness is to the maximum willingness to pay. In many situations, the adjustment may not result in a change in policy recommendations.
ACCESSION #
70064074

 

Related Articles

  • Health economics: the end of clinical freedom? Williams, Allan // BMJ: British Medical Journal (International Edition);11/5/88, Vol. 297 Issue 6657, p1183 

    Focuses on the status of clinical freedom of physicians in Great Britain. Impact of health economics on physicians; Consideration of the cost of medical services in the practice of doctors; Importance of doctor-patient relationship.

  • Particle therapy in clinical practice: Is there enough evidence to justify the current surge in interest? Jalali, Rakesh // Journal of Cancer Research & Therapeutics;Apr-Jun2008, Vol. 4 Issue 2, p54 

    The author reflects on the growing enthusiasm for particle therapy in clinical practice. He argues that the interest in particle therapy presents an opportunity to discuss the need for assessment of radiotherapy techniques and technology-driven practices in medicine. He examines the progress...

  • Impact of a Cost Visibility Tool in the Electronic Medical Record on Antibiotic Prescribing in an Academic Medical Center. Fargo, Kelly L.; Johnston, Jessica; Stevenson, Kurt B.; Deutscher, Meredith; Reed, Erica E. // Hospital Pharmacy;Jun2015, Vol. 50 Issue 6, p496 

    Background: Studies evaluating the impact of passive cost visibility tools on antibiotic prescribing are lacking. Objective: The objective of this study was to evaluate whether the implementation of a passive antibiotic cost visibility tool would impact antibiotic prescribing and decrease...

  • Prescription of Generic Drugs. Chaudhari, Mayur; Charan, Jaykaran // National Journal of Physiology, Pharmacy & Pharmacology;2013, Vol. 3 Issue 1, p1 

    The author comments on prescription of generic medicines, which are manufactured without licence from original innovator manufacturer. He says that the cost of medicines is one of the major components of increased cost of healthcare related expenses. 78% of patients spent money on health...

  • Thematic stream: inflammatory arthritis. Vermeer, Marloes; Kuper, Ina; Hoekstra, Monique; Moens, Hein Bernelot; Posthumus, Marcel; Brus, Herman; van Riel, Piet; van de Laar, Mart // Rheumatology;Feb2011 Supplement 2, Vol. 50 Issue suppl_2, pii1 

    Background: Remission is the primary therapeutic goal in rheumatoid arthritis (RA). Clinical trials have proven that systematic monitoring of disease activity, adjusting medication accordingly and aiming at a predefined target is effective in reaching this goal. However, aiming for remission is...

  • Economies of scale.  // GP: General Practitioner;6/24/2005, p17 

    The article informs that an economy of scale factor should be put into the global sum to help smaller practices. Local medical committee representatives backed a motion to help smaller practices with higher administration and staffing costs.

  • Recruitment Rates and Data Quality. Platonov, Pyotr G.; Escandon, Rafael; Varshavsky, Sergei // Applied Clinical Trials;Nov2003, Vol. 12 Issue 11, p32 

    No abstract available.

  • Trial Site Insight: Will Your Trial Master File Pass FDA Inspection?  // BioWorld Insight;1/25/2010, Vol. 18 Issue 4, p2 

    The article reports on the warning letters sent by the Center for Drug Evaluation and Research (CDER) to trial for good clinical practice in the U.S.

  • Physician cost-profiling may be misleading.  // Infectious Diseases in Children;Apr2010, Vol. 23 Issue 4, p48 

    This article discusses a study on methods of profiling physicians in the U.S. based on the cost of care.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics